Market revenue in 2023 | USD 80.0 million |
Market revenue in 2030 | USD 167.0 million |
Growth rate | 11.1% (CAGR from 2023 to 2030) |
Largest segment | Ctc detection & enrichment methods |
Fastest growing segment | CTC Analysis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis |
Key market players worldwide | Qiagen NV, Bio-Techne Corp, Praxis Precision Medicines Inc Ordinary Shares, Aviva PLC, Biocept Inc, Neurocrine Biosciences Inc, Greiner Bio-One, Miltenyi Biotec, Icon PLC, Ecolab Inc, Arcus Biosciences Inc, Epic Corp, Screen Holdings Co Ltd, Menarini Group, Vtex Ordinary Shares - Class A, Sysmex Corp, STEMCELL Technologies |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to circulating tumor cells market will help companies and investors design strategic landscapes.
Ctc detection & enrichment methods was the largest segment with a revenue share of 66.75% in 2023. Horizon Databook has segmented the Mexico circulating tumor cells market based on ctc detection & enrichment methods, ctc direct detection methods, ctc analysis covering the revenue growth of each sub-segment from 2018 to 2030.
Mexico is the second-largest pharmaceutical market in Latin America followed by Brazil. The branded generics market is anticipated to witness moderately high growth over the forecast period owing to increasing investments by generic players coupled with government initiatives.
According to the National Association of Drug Manufacturers, 86% of pharmaceuticals used in the country are produced internally, which makes the country highly self-sufficient. In addition, strategic initiatives by global players further accelerate market growth.
As per a survey in 2019, around 87.2% of Mexican patients buy generic products, which is anticipated to drive market growth. Moreover, regulatory bodies in the country, such as COFEPRIS, are undertaking various strategic initiatives to increase availability generic drugs in the Mexican market, thereby reducing the out-ofpocket spending of individuals.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico circulating tumor cells market , including forecasts for subscribers. This country databook contains high-level insights into Mexico circulating tumor cells market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account